Clinical Trial

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Study acronym: MAMBO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 28, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-10; most recent amendment 2024-10-24.
Trial Details
NCT Number NCT06503848
Lead Sponsor Hospital Universitari Vall d'Hebron Research Institute
Collaborators: Instituto de Salud Carlos III
Conditions Migraine Disorders
Enrollment 108 participants
Start Date 2024-01-25
Primary Completion 2024-12 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-28